GLLI
Globalink Investment Inc.3.0000
-8.5000-73.9%
Oct 30, 4:00:00 PM EDT
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
10.55MP/E (TTM)
-Basic EPS (TTM)
-0.36Dividend Yield
0%Recent Filings
8-K
Unanimous approval for Alps merger
Globalink Investment Inc. stockholders unanimously approved the business combination with Alps Life Sciences on October 7, 2025, including the redomestication merger into PubCo and the acquisition merger making Alps a wholly-owned subsidiary. They also greenlit a charter amendment removing the $5,000,001 net tangible assets requirement for the deal. With 59,966 public shares redeemed, only 12,635 remain outstanding. Unanimous votes signal strong alignment.
8-K
Merger agreement amended again
Globalink Investment Inc. signed a third amendment to its merger agreement with Alps Life Sciences Inc. on September 27, 2025, permitting Dr. Tham Seng Kong to contribute his personal escrow shares as merger consideration and extending the shareholder consent deadline. This tweak sustains momentum for the de-SPAC deal amid ongoing SEC filings. Deal closure remains uncertain. Risks include failure to secure approvals or stockholder votes.
8-K
SPAC extends deadline again
Globalink Investment Inc. extended its deadline to complete an initial business combination by one month to October 9, 2025, via a $10,890.15 deposit into its trust account at $0.15 per public share. This marks the twenty-seventh extension since its 2021 IPO and the fourth under current rules. The move buys time for a merger in medtech or green energy. Yet risks loom large.
10-Q
Q2 FY2025 results
Globalink Investment Inc. posted a net loss of $893,896 for Q2 FY2025 ended June 30, 2025, wider than the $217,185 loss a year earlier, driven by $451,629 in interest expense on convertible notes and $133,677 in tax penalties, offset by $34,237 in trust interest income. Year-to-date, the net loss hit $1,632,451, up from $592,492, with operating expenses down to $637,683 from $1,066,744 while trust income fell to $66,336 from $687,312 due to lower balances post-redemptions. Cash dwindled to $22,170 amid a $7.9 million working capital deficit, yet the $3.73 million trust provides a buffer for the pending merger with Alps Life Sciences Inc., amended multiple times to ease terms like removing net asset thresholds. Convertible notes totaling $4.6 million net, due to related parties, carry 6% interest and convert at $10 per share post-closing. Delisting from Nasdaq to OTC Pink adds friction. Merger delays risk liquidation by September 9, 2025.
8-K
Financial restatement announced
Globalink Investment Inc. disclosed on August 14, 2025, that its 2024 audited financials and Q1 2025 statements can't be relied on due to errors in redemption payments from a December 2024 stockholder meeting, where redeeming shareholders got overpaid $0.24643075 per share because not all allowable interest was withdrawn for taxes. This miscalculation also skewed the per-share redemption price below the initial $10.15, ignoring extra extension payments into the trust. The company plans restatements via amended 10-K and 10-Q filings, expecting to uncover material weaknesses in internal controls. Restatements expose accounting flaws.
AACI
Armada Acquisition Corp. II
10.29-0.01
AIMTF
Aimfinity Investment Corp. I
7.07-4.03
CBGGF
Chain Bridge I
10.91+0.00
FTII
FutureTech II Acquisition Corp.
12.02+0.00
GRAF
Graf Global Corp.
10.71-0.14
GTERA
Globa Terra Acquisition Corpora
10.08-0.01
IGTA
Inception Growth Acquisition Li
8.25+0.00
IMAQ
International Media Acquisition
9.72+0.00
SPKL
Spark I Acquisition Corp.
11.23+0.08
YOTA
Yotta Acquisition Corporation
2.00+0.00